相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy
Masashi Mikubo et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
Heidie Frisco Cabanos et al.
CANCERS (2021)
Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
Huayi Li et al.
CANCERS (2021)
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
F. Mosele et al.
ANNALS OF ONCOLOGY (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives
Claudio Vernieri et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer
Francois M. Vallette et al.
BIOCHEMICAL PHARMACOLOGY (2019)
Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient
Yosuke Hirotsu et al.
MEDICAL ONCOLOGY (2017)
Mutational analysis of multiple lung cancers: Discrimination between primary and metastatic lung cancers by genomic profile
Taichiro Goto et al.
ONCOTARGET (2017)
CDK4/6 inhibitors in HER2-positive breast cancer
Silvia Paola Corona et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Touch imprint cytology with massively parallel sequencing (TIC-seq): a simple and rapid method to snapshot genetic alterations in tumors
Kenji Amemiya et al.
CANCER MEDICINE (2016)
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity
Alexandra Van Keymeulen et al.
NATURE (2015)
PIK3CAH1047R induces multipotency and multi-lineage mammary tumours
Shany Koren et al.
NATURE (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer
Yosuke Hirotsu et al.
MOLECULAR GENETICS & GENOMIC MEDICINE (2015)
COSMIC: exploring the world's knowledge of somatic mutations in human cancer
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2015)
Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing
Yosuke Hirotsu et al.
MOLECULAR GENETICS & GENOMIC MEDICINE (2015)
Resistance to human epidermal growth factor receptor type 2-targeted therapies
Jean-Christophe Thery et al.
EUROPEAN JOURNAL OF CANCER (2014)
PyClone: statistical inference of clonal population structure in cancer
Andrew Roth et al.
NATURE METHODS (2014)
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy et al.
NATURE GENETICS (2013)
The landscape of cancer genes and mutational processes in breast cancer
Philip J. Stephens et al.
NATURE (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
PTEN, PIK3CA, p-AKT, and p-p70S6K Status Association with Trastuzumab Response and Survival in Patients with HER2-Positive Metastatic Breast Cancer
Francisco J. Esteva et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients
Jeff Sperinde et al.
CLINICAL CANCER RESEARCH (2010)
Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review
Shaheenah Dawood et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
Michael Untch et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni et al.
LANCET (2010)
An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance
Doyel Mitra et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB Ligands and remain dependent on the ErbB receptor network
Christoph A. Ritter et al.
CLINICAL CANCER RESEARCH (2007)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
AU Buzdar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
YH Lu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
